Today's show, a special co-production with MPR News.

节目是与 MPR News 特别联合制作。

The MPR rate was encouraging at 83%, and the pCR rate was 63%.

MPR 率为 83%，令人鼓舞，pCR 率为 63%。

Phase lI studies have shown that neoadjuvant immunotherapy, with or without chemotherapy, induces high MPR rates.

II 期研究明，助免疫疗法，无论是否联合化疗，均可诱导较高 MPR 率。

Baseline PD-L1 expression was shown to correlate with response and MPR in one study.

一项研究显示，基线 PD-L1 达与反应和 MPR 相关。

MPR, the assessment of toxicities and the percentage of patients not getting to surgery, have become the main foci of Phase II studies evaluating neoadjuvant immunotherapy (Table 5.4).

MPR，即毒性评估和未接受手术患者百分比，已成为评估助免疫治疗 II 期研究主要焦点（ 5.4）。

Major pathological response (MPR) is defined as 10% residual viable tumor in a resected specimen after neoadjuvant treatment, and has been shown to correlate with OS in patients who received chemotherapy.

主要病理缓解 (MPR) 定义为助治疗后切除标本中残留有 10% 存活肿瘤，并已被证明与接受化疗患者 OS 相关。

While MPR was not reported, 60% of patients showed radiographic response after neoadjuvant durvalumab and chemotherapy, and 73% of patients remained event-free at 1 year, 27 much higher than historical figures with surgery and chemotherapy alone.

虽然没有报道 MPR，但 60% 患者在助 durvalumab 和化疗后现出放射学缓解，73% 患者在 1 年后保持无事件，27 远高于仅手术和化疗历史数据。